Flexzo AI raises £9m to automate NHS rostering and cut agency costs
This article covers Flexzo AI, a London-based healthtech startup, which has raised £9m in a series A funding round to scale its AI-powered workforce management platform for hospitals and healthcare providers. The funding is intended to support roll-out across additional NHS Trusts, reduce reliance on agency staff and administrative overheads, and accelerate the startup's planned expansion into the US healthcare market.
London-based healthtech startup Flexzo AI has raised £9m in a series A funding round to scale its AI-powered workforce management platform for hospitals and healthcare providers. The cash injection is intended to support roll-out across more NHS Trusts and speed the company’s planned entry into the US healthcare market.
Why it matters
Hospitals in the UK are under sustained pressure from staffing shortages and rising agency costs, and much of the operational tooling they use has not kept pace. Flexzo AI targets those day-to-day inefficiencies — rostering gaps, fragmented compliance checks and limited visibility into available staff — with software designed to reduce reliance on external agencies and cut administrative overheads.
Early deployments across NHS Trusts have reportedly produced measurable operational savings and efficiency improvements, suggesting the product is addressing practical, non-clinical pain points that directly affect service delivery and costs.
Inside the product
Flexzo’s platform brings together a pre-verified talent pool for sourcing both temporary and permanent clinical staff and includes modules for rostering, internal staff bank management, float pool coordination and compliance workflows. A key distinction the company makes is that the system is “agentic”: rather than only offering dashboards and analytics, it is designed to automate routine workforce processes and decision flows — for example, matching shifts to available staff, enforcing compliance checks and triggering internal reallocation before an external agency is engaged.
The product claims to avoid agency fees by enabling hospitals to source staff directly from verified pools. The company plans to use the new funding to expand engineering and commercial resources and to continue developing the underlying AI models that drive those automated decisions.
Who are the investors?
The round was led by Octopus Ventures, with participation from Fuel Ventures. The investment totals £9m and will be used to grow the engineering and commercial teams, further develop AI capabilities and scale adoption across healthcare systems facing ongoing staffing shortages.
In the announcement, Uthish Ranjan, Partner at Octopus Ventures, said:
We are excited to support Flexzo in applying AI where it truly matters. The strong ROI impact already delivered across NHS Trusts, alongside early traction in the US, demonstrates both the urgency of the problem and the strength of the product.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Flexzo AI was founded in 2023 by Jack Henderson, who previously ran a clinical insourcing company that delivered services to NHS patients. Henderson says those frontline experiences informed the product’s focus on compliance fragmentation and costly agency dependence.
In the announcement, Jack Henderson, Founder of Flexzo AI, said:
Healthcare organisations are still managing their workforce using processes that haven’t fundamentally evolved in decades.
Hospitals should not be forced to rely on inefficient systems and spiralling agency costs. With Flexzo AI, we are delivering a step change in workforce efficiency that healthcare systems urgently need.
The bigger picture
This funding sits at the intersection of two trends: growing interest in operational AI that reduces costs and the continued search for solutions to NHS staffing shortages. The emphasis on automating non-clinical workflows differentiates companies like Flexzo from healthtech firms focused on diagnostics or patient-facing tools.
The deal also underscores appetite among healthtech investors for businesses that can demonstrate tangible ROI in UK care settings and translate those results into international markets. For UK startups building operational solutions, convincing NHS procurement teams and proving regulatory compliance remain crucial steps before wider adoption.
As Flexzo scales, its progress will offer an early test of whether agentic workforce automation can deliver sustainable savings for hospitals and become a viable export for UK healthtech into larger markets such as the US.
They've invested in Flexzo AI
Get to know these healthtech investors
Click here for a full list of 7,526+ startup investors in the UK